Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Chinook Therapeutics, Inc. (KDNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
19.22+0.76 (+4.12%)
At close: 04:00PM EDT
19.22 0.00 (0.00%)
After hours: 04:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close18.46
Open18.69
Bid16.00 x 1000
Ask19.23 x 1100
Day's Range18.43 - 19.24
52 Week Range10.48 - 23.86
Volume399,184
Avg. Volume577,382
Market Cap1.209B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KDNY

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Chinook Therapeutics, Inc.
    The Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID stocks) have underperformed large-caps over the past 12 months, but still may be in a better position to generate market-beating returns going forward. For one thing, SMID companies tend to focus on domestic markets, so their businesses could be less disrupted by the fallout from the Russian invasion of Ukraine. As well, the prices of SMID stocks generally are lower than the prices of large-caps. SMID stocks can be risky -- and large-caps outperformed SMID stocks in 11 of the 19 years in our test period. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. We estimate that 12%-15% of the U.S. stock market's capitalization is comprised of SMID stocks. For our purposes, we use a threshold of $20 billion to define a SMID stock.
    Rating
    Fair Value
    Economic Moat
    yesterdayArgus Research
View more
  • GlobeNewswire

    Chinook Therapeutics to Present at Upcoming Investor Conferences

    SEATTLE, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in fireside chats and one-on-one meetings at the following upcoming investor conferences: 2022 Wells Fargo Healthcare Conference – Fireside chat on Thursday, September 8th at 1:20 pm EDT. Morgan Stanley 20th Annua

  • GlobeNewswire

    Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results

    SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and six months ended June 30, 2022. “During the second quarter of 2022, we executed well on advancing our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We conti

  • GlobeNewswire

    Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    SEATTLE, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase a total of 24,700 shares of common stock with a grant date of July 29, 2022 (the “Inducement Grant”) for one new employee. The

Advertisement
Advertisement